Education about the necessity and safety of vaccines and their role in preventing childhood disease.
Issues related to pharmaceutical pricing in general (no specific legislation)
Duration: February 1, 2008
to
August 31, 2017
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Pharmacy , Economics/Economic Development , Copyright/Patent/Trademark , Manufacturing , Budget/Appropriations , Disaster Planning/Emergencies , Animals , Torts , Government Issues
Spending: about $1,150,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate, U.S. Senate,, House of Representatives,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Patricia Knight Chf of Staff, Sen. Orrin Hatch; Hlth Plcy Dir, Sen. Hatch;
Actg DAS for Legis, DHHS; Prof Staff, House Apprps Cmte;
Prin DAS for Leg Affrs, Dept of Cmmrce; DAS for Legis, DHHS
Chief of Staff, Sen. Orrin G. Hatch
Previously reported
Health Policy Director, Sen. Orrin Hatch
Acting DAS/DAS for Legislation, DHHS
Prncpl DAS for Legis/Intergvtl Affrs, DoC
Professional Staff, House Approps Cmte
previously listed
Previously Listed
(previously listed)
(Previously listed)
Health Policy Dir, Sen. Orrin G. Hatch
Acting DAS/DAS for Legis, DHHS
Prncpl DAS for Legis/Intrgvtl Affrs, DoCommerce
Prof. Staff, House Appropriations Committee
Chf of Staff; Hlth Policy Dir, Sen. Orrin Hatch
Acting DAS for Legis, DAS for Legis (Hlth) HHS
Prncpl DAS for Legis/Intrgvtl, Dpt of Commerce
Prof. Staff Member, House Apprps Cmte
Acting DAS for Legis; DAS for Hlth Legis, HHS
Princpl DAS for Legis/Intrgvtl Affrs, Dept of Cmrc
Prof. Staff Member, House Approps Cmte
Chief of Staff; Hlth Plcy Dir, Sen. Orrin Hatch
Acting DAS for Leg; DAS for Leg, HHS
Prin DAS for Leg/Intergvtl Affrs, Dpt of Cmrce
Chief of Staff, Hlth Plcy Dir, Sen Orrin Hatch
Acting DAS for Leg; DAS for Leg (HHS)
Prof Staff Member, House Approps Cmte
Prin DAS for Leg/Intergvtl Affrs, Dept of Cmrce
Chief of Staff/Hlth Plcy Dir, Sen. Orrin Hatch
Patricia Knight cont'd Actg DAS/DAS for Leg, DHHS
Prof Staff, House Apprps Cmte
Prin DAS for Legis, Intrgvtl, Dept of Cmmrce
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2017
Knight Capitol Consultants terminated an engagement in which they represented Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) on Oct. 19, 2017.
Original Filing: 300910119.xml
Lobbying Issues
Education about the necessity and safety of vaccines and their role in preventing childhood disease.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing in general (no specific legislation)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300894528.xml
Lobbying Issues
Education about the necessity and safety of vaccines and their role in preventing childhood disease.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor issues of interest to pharmaceutical companies (no specific bills)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B reimbursement and the Medicare Part D program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Track development of the Food and Drug Administration Reauthorization Act (H.R. 2430/S. 934) and issues of interest to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 12, 2017.
Original Filing: 300864463.xml
Lobbying Issues
Education about the necessity and safety of vaccines; American Health Care Act (HR 1628); general issues related to the 340B drug pricing program;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues of interest to pharmaceutical companies (no specific bills)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B reimbursement and the Medicare Part D program
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856182.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Act (PL 114-255); and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (Further Continuing and Security Assistance Appropriations Act, PL 114-254). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases and insulin pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax provisions and regulations having an impact on corporations (no specific bills).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in or changes to reimbursement for medicines under the Medicare Part B program; and Senate Finance Chronic Care Work Group (no specific legislation).
3rd Quarter, 2016
In Q3, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Oct. 20, 2016.
Original Filing: 300839510.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax provisions and regulations having an impact on corporations (no specific bills).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in or changes to reimbursement for medicines under the Medicare Part B program; and Senate Finance Chronic Care Work Group (no specific legislation).
2nd Quarter, 2016
In Q2, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on July 20, 2016.
Original Filing: 300818948.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks -Zika Response Appropriations Act (HR 5243), Tropical Disease PRV Program (S.2512/H.R.4400); and Strengthening Public Health Emergency Response Act (HR 3299).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax provisions having an impact on corporations (no specific bills).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
The importance of foreign direct investment in the United States (no bill number)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in or changes to reimbursement for medicines under the Medicare Part B program; and Senate Finance Chronic Care Work Group (no specific legislation).
Lobbying Issues
Patent law changes affecting the pharmaceutical industry (S. 1137 - Patent Act)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2016
In Q1, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300796553.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative (HR 6); the Safe and Affordable Drugs from Canada Act (S. 122) or possible amendments to legislation affecting the importation of prescription drugs; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA and NIH (Consolidated Appropriations Act, PL 114-113). Possible changes to the 340B drug pricing program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax provisions having an impact on corporations (no specific bills).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
The importance of foreign direct investment in the United States (no bill number)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in or changes to reimbursement for medicines under the Medicare Part B program; and Senate Finance Chronic Care Work Group (no specific legislation).
Lobbying Issues
Patent law changes affecting the pharmaceutical industry (S. 1137 - Patent Act)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2015
In Q4, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781918.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative (HR 6); the Safe and Affordable Drugs from Canada Act (S. 122) or possible amendments to legislation affecting the importation of prescription drugs; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA and NIH (Consolidated Appropriations Act, PL 114-113). Possible changes to the 340B drug pricing program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax provisions having an impact on corporations, including the R&D tax credit (Protecting Americans from Tax Hikes Act of 2015, Rules Committee Print 114-113, PL 114-113)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
The importance of foreign direct investment in the United States (no bill number)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in reimbursement for medicines under the Medicare Part B program; possible amendments to the "Medicare Access and CHIP Reauthorization Act" (S. 2); and Senate Finance Chronic Care Work Group (no specific legislation).
Lobbying Issues
Patent law changes affecting the pharmaceutical industry (S1137 - Patent Act)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 22, 2015.
Original Filing: 300766371.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative (HR 6); the Safe and Affordable Drugs from Canada Act (S. 122) or possible amendments to legislation affecting the importation of prescription drugs; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA and NIH. Possible changes to the 340B drug pricing program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive tax reform and its impact on corporations, including the R&D tax credit (no specific legislation)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
The importance of foreign direct investment in the United States (no bill number)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in reimbursement for medicines under the Medicare Part B program; possible amendments to the "Medicare Access and CHIP Reauthorization Act" (S. 2); and Senate Finance Chronic Care Work Group (no specific legislation).
Lobbying Issues
Patent law changes affecting the pharmaceutical industry (S1137 - Patent Act)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 16, 2015.
Original Filing: 300737140.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; The Medical Innovation Act (S. 320/H.R. 744); the 21st Century Cures Initiative (HR 6); the Safe and Affordable Drugs from Canada Act (S. 122) or possible amendments to legislation affecting the importation of prescription drugs; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA and NIH. Possible changes to the 340B drug pricing program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive tax reform and its impact on corporations, including the R&D tax credit (no specific legislation)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
The importance of foreign direct investment in the United States (no bill number)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in reimbursement for medicines under the Medicare Part B program; possible amendments to the "Medicare Access and CHIP Reauthorization Act" (S. 2); and Senate Finance Chronic Care Work Group (no specific legislation).
Lobbying Issues
Patent law changes affecting the pharmaceutical industry (HR -Innovation Act; S1137 - Patent Act)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300724055.xml
Lobbying Issues
Education and awareness of the need for immunizations, pandemic/biodefense funding; The Medical Innovation Act (S. 320/H.R. 744); the 21st Century Cures Initiative (no bill number yet); the Safe and Affordable Drugs from Canada Act (S. 122) or possible amendments to legislation affecting the importation of prescription drugs; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA and NIH. Possible changes to the 340B drug pricing program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive tax reform and its impact on corporations, including the R&D tax credit (no specific legislation)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
The importance of foreign direct investment in the United States (no bill number yet)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in reimbursement for medicines under the Medicare Part B program; and possible amendments to the "Medicare Access and CHIP Reauthorization Act" (S. 2).
4th Quarter, 2014
In Q4, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300705557.xml
Lobbying Issues
Combination Drug Development Incentive Act of 2013 (HR 2985)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor possible changes in the tax code affecting corporations, including corporate income tax reform, corporate "inversions", and a strengthened U.S. R&D tax credit (no specific legislation).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the US, including the Global Investment on American Jobs Act (HR 2052/ S1023)
Agencies Lobbied
U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (Sustainable Growth Rate Repeal and Medicare Beneficiary Access Improvement Act (S 1871)/Protecting Access to Medicare Act of 2014 (HR 113-93).
3rd Quarter, 2014
In Q3, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 20, 2014.
Original Filing: 300687977.xml
Lobbying Issues
Monitor implementation of the Drug Quality and Security Act (PL 113-54).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Combination Drug Development Incentive Act of 2013 (H.R. 2985, no Senate bill number yet).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting corporations, including corporate income tax reform, corporate "inversions", and a strengthened U.S. R&D tax credit (no specific legislation).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the United States, including the Global Investment in American Jobs Act (HR 2052/S. 1023).
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (Sustainable Growth Rate Repeal and Medicare Beneficiary Access Improvement Act (S. 1871)/Protecting Access to Medicare Act of 2014 (H.R. 4302/Public Law 113-93).
2nd Quarter, 2014
In Q2, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 18, 2014.
Original Filing: 300662884.xml
Lobbying Issues
Monitor implementation of the Drug Quality and Security Act (PL 113-54).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Combination Drug Development Incentive Act of 2013 (H.R. 2985, no Senate bill number yet).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting corporations, including corporate income tax reform and a strengthened U.S. R&D tax credit (no specific legislation).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the United States, including the Global Investment in American Jobs Act (HR 2052/S. 1023).
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (Sustainable Growth Rate Repeal and Medicare Beneficiary Access Improvement Act (S. 1871)/Protecting Access to Medicare Act of 2014 (H.R. 4302/Public Law 113-93).
1st Quarter, 2014
In Q1, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 18, 2014.
Original Filing: 300641605.xml
Lobbying Issues
Monitor implementation of the Drug Quality and Security Act (PL 113-54).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Combination Drug Development Incentive Act of 2013 (H.R. 2985).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting corporations, including corporate income tax reform and a strengthened U.S. R&D tax credit (no specific legislation).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the United States, including the Global Investment in American Jobs Act (HR 2052/S. 1023).
Type of Issue
Economics/Economic Development
Lobbying Issues
Issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (Sustainable Growth Rate Repeal and Medicare Beneficiary Access Improvement Act (S. 1871)/Protecting Access to Medicare Act of 2014 (H.R. 4302/Public Law 113-93).
4th Quarter, 2013
In Q4, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 21, 2014.
Original Filing: 300624602.xml
Lobbying Issues
Drug Quality and Security Act (PL 113-54)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
User fee sequester/implementation issues related to PL 112-144, including User Fee Sequester Relief Act (HR 2775/S. 1413); changes to the Affordable Care Act (PL 111-148)/Health Care & Education Reconciliation Act (PL 111-152), including Independent Payment Advisory Board; compounding of human/animal drugs (Pharmaceutical Compounding Quality and Accountability Act, PL 113-54); School Access to Emergency Epinephrine Act (PL 113-182).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting corporations, including corporate income tax reform and a strengthened U.S. R&D tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the United States, including the Global Investment in American Jobs Act (HR 2052/ S. 1023)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Effect of sequester on public health programs, biomedical research, and the Food and Drug Administration (FY 2014 appropriations for FDA-H.R. 2410/S. 1244/FY 2014 appropriations for HHS- S. 1284/Continuing Resolution H.J. Res. 59); User Fee Sequester Relief Act (HR 2775/S. 1413).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to changes in the Medicare Part B reimbursement of prescription drugs; and issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (no specific legislation).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 16, 2013.
Original Filing: 300595316.xml
Lobbying Issues
Drug Quality and Security Act (H.R. 3204; S. 959)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
User fee sequester/implementation issues related to PL 112-144; changes to the Affordable Care Act (PL 111-148)/Health Care & Education Reconciliation Act (PL 111-152), including Independent Payment Advisory Board; compounding of human/animal drugs (Pharmaceutical Compounding Quality and Accountability Act, S. 959); School Access to Emergency Epinephrine Act (H.R. 2094/ S. 1503)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting corporations, including corporate income tax reform and a strengthened U.S. R&D tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the United States, including the Global Investment in American Jobs Act (HR 2052/ S. 1023)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Effect of sequester on public health programs, biomedical research, and the Food and Drug Administration (FY 2014 appropriations for FDA-H.R. 2410/S. 1244/FY 2014 appropriations for HHS- S. 1284/Continuing Resolution H.J. Res. 59).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to changes in the Medicare Part B reimbursement of prescription drugs; and issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (no specific legislation).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 18, 2013.
Original Filing: 300575652.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits ("Fair and Immediate Release of Generic Drugs Act", S. 504) and possible addition of this or similar text to other legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
User fee sequester/implementation issues related to PL 112-144; changes to the Affordable Care Act (PL 111-148)/Health Care & Education Reconciliation Act (PL 111-152), including Independent Payment Advisory Board; compounding of human/animal drugs (Pharmaceutical Compounding Quality & Accountability Act, S. 959); "track and trace" (H.R. 1919, Safeguarding America's Pharmaceuticals Act); Animal Drug User Fee Amendments (PL 113-14); School Access to Emergency Epinephrine Act (HR 2094)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting pharmaceutical corporations; include quadrivalent influenza vaccine in the Vaccine Injury Compensation Program (P.L. 113-15).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Foreign direct investment in the United States, including the Global Investment in American Jobs Act (HR 2052/ S. 1023)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Effect of sequester on public health programs, biomedical research, and the Food and Drug Administration (FY 2014 appropriations for FDA-H.R. 2410/S. 1244) (FY 2014 appropriations for HHS- S. 1284).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to changes in the Medicare Part B reimbursement of prescription drugs; and issues related to coverage and reimbursement for the Medicare and Medicaid programs, including the Part D prescription drug benefit (no specific legislation).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 22, 2013.
Original Filing: 300560720.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits ("Fair and Immediate Release of Generic Drugs Act" (S. 504) and possible addition of this or similar text to other legislation).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Pharmaceutical issues, including: sequester of user fees and implementation issues associated with the FDA Safety and Innovation Act (PL 112-144); changes to the Patient Protection and Affordable Care Act (PL 111-148) and Health Care & Education Reconciliation Act of 2010 (PL 111-152), including the Independent Payment Advisory Board; compounding of human and animal drugs (no specific legislation); and the Animal Drug User Fee Act Amendments (S. 622/H.R. 1408)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor possible changes in the tax code affecting pharmaceutical corporations; inclusion of quadrivalent influenza vaccine in the Vaccine Injury Compensation Program (H.R. 475/S. 391).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General issues related to foreign direct investment in the United States, including the Global Investment in American Jobs Act (no legislation introduced yet).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Effect of sequester on public health programs, biomedical research and the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to changes in the Medicare Part B reimbursement of prescription drugs; and issues related to coverage and reimbursement for those who are covered by the Medicare and Medicaid programs, including the Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Pandemic and All Hazards Preparation Reform Act (HR 307/S 242, PL 113-5)
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2012
In Q4, Knight Capitol Consultants lobbied for Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 16, 2013.
Original Filing: 300530234.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and possible addition of this or similar text to other legislation).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Pharmaceutical issues, including Food and Drug Administration Safety and Innovation Act (PL 112-144), changes to the Patient Protection and Affordable Care Act (PL 111-148) Health Care & Education Reconciliation Act of 2010 (PL 111-152),
including the Independent Payment Advisory Board; importation of prescription drugs; and S. 1884/H.R. 3627, School Access to Emergency Epinephrine Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142); extension of the Tax Extenders Legislation (P.L. 111-312) and such provisions included in The American Taxpayer Relief Act (P.L. 112-240); and inclusion of quadrivalent influenza vaccine in the Vaccine Injury Compensation Program (S. 3716).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General issues related to foreign direct investment in the United States, including the Global Investment in American Jobs Act of 2012 (H.R. 5910/S. 3274).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Effect of possible sequester on public health programs, biomedical research and the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Great Ape Protection and Cost Saving Act of 2011 (S. 810/H.R. 1513)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to changes in the Medicare Part B reimbursement of prescription drugs; and issues related to coverage and reimbursement for those who are covered by the Medicare and Medicaid programs, including the Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511155.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and its possible addition to other legislation, including Food and Drug Administration Safety and Innovation Act and FY 2013 appropriations bills.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Pharmaceutical issues, including Food and Drug Administration Safety and Innovation Act (PL 112-144), changes to the Patient Protection and Affordable Care Act (PL 111-148) Health Care & Education Reconciliation Act of 2010 (PL 111-152),
including the Independent Payment Advisory Board; Medicare reimbursement; access to diabetes care and atrial fibrillation care
(H. Res. 295, S. Res. 243), importation of prescription drugs; and S. 1884, School Access to Emergency Epinephrine Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142), extension of the Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942), and the "Greater Research Opportunities with Tax Help Act" (S. 1577).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compensation Program to include quadrivalent influenza vaccine (no legislation yet).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General issues related to foreign direct investment in the United States, including the Global Investment in American Jobs Act of 2012 (H.R. 5910/S. 3274).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Effect of possible sequester on public health programs, biomedical research and the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on July 19, 2012.
Original Filing: 300490875.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and its possible addition to other legislation; S. Amndmt 2111 to S. 3187, Prescription Drug User Fee Act extension).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Pharmaceutical issues, including PDUFA V (S. 3187/H.R.5651) , changes to the Patient Protection and Affordable Care Act (PL 111-148) Health Care & Education Reconciliation Act of 2010 (PL 111-152) including the Independent Payment Advisory Board; Medicare reimbursement; access to diabetes care and atrial fibrillation care (H.Res. 295, and S.Res.243); importation of
prescription drugs (S. Amndt 2107 to S. 3187); S. 1884, School Access to Emergency Epinephrine Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142), Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942), and the "Greater Research Opportunities with Tax Help Act" (S. 1577).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compensation Program (no legislation yet)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General issues related to foreign direct investment in the United States, including the Global Investment in American Jobs Act of 2012 (H.R. 5910/S. 3274).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
1st Quarter, 2012
In Q1, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on April 22, 2012.
Original Filing: 300475858.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and its possible addition to other legislation).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Pharmaceutical issues, including PDUFA V, changes to the Patient Protection and Affordable Care Act (PL 111-148) Health Care & Education Reconciliation Act of 2010 (PL 111-152) including the Independent Payment Advisory Board; Medicare reimbursement; access to diabetes care and atrial fibrillation care, including H.Res. 295, and S.Res.243; importation of prescription drugs. Possible restrictions on products containing pseudoephedrine. S. 1884, School Access to Emergency Epinephrine Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142), Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942), and the "Greater Research Opportunities with Tax Help Act" (S. 1577).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compensation Program (no legislation yet)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Jan. 20, 2012.
Original Filing: 300447592.xml
Lobbying Issues
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and deliberations of Deficit Reduction Committee).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Pharmaceutical industry issues, including: implementation of, changes to, or repeal of all or parts of the Patient Protection and Affordable Care Act (PL 111-148)/Health Care and Education Reconciliation Act of 2010 (PL 111-152) including the Independent Payment Advisory Board; reimbursement in Medicare Parts B and D; access to diabetes care and atrial fibrillation care, including H.Res. 295, and S. Res. 243; and importation of prescription drugs, amendment 769 to H.R. 2112, Continuing Appropriations.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142), Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942), and the "Greater Research Opportunities with Tax Help Act" (S. 1577).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compensation Program (no legislation yet)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Oct. 19, 2011.
Original Filing: 300422027.xml
Lobbying Issues
Provisions related to the pharmaceutical industry in the Leahy-Smith America Invents Act (P.L. 112-29)
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and deliberations of Deficit Reduction Committee).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry with respect to implementation of, possible changes in, or repeal of all or parts of the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152), including the Independent Payment Advisory Board, coverage of pharmaceuticals under Medicare Parts B and D; and awareness and issues related to access to diabetes care and also atrial fibrillation care, including H.Res. 295, S. Res. 243.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142), Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compensation Program (no legislation yet)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General issues related to reauthorization of the Pandemic and All Hazards Preparedness Act (no legislation yet)
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2011
In Q2, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on July 20, 2011.
Original Filing: 300402976.xml
Lobbying Issues
Patent Reform provisions related to pharmaceutical industry-America Invents Act (H.R. 1249), Patent Reform Act of 2011 (S. 23)
Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry with respect to implementation of, possible changes in, or repeal of all or parts of the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152), including the Independent Payment Advisory Board, Medicare Part D; and awareness and issues related to access to diabetes care and also atrial fibrillation care, including H.Res. 295.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (P.L. 111-142), Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942).
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compensation Program (no legislation yet)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on April 20, 2011.
Original Filing: 300377220.xml
Lobbying Issues
Implementation of, or possible changes to the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
America Invents Act (H.R. 1249); Patient Reform Act of 2011 (S. 23)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Possible extension of the R&D tax credit (no specific legislation)
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Possible changes to the Vaccine Injury Compension program (no legislation introduced)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Jan. 19, 2011.
Original Filing: 300345768.xml
Lobbying Issues
Patent Reform - Issues of interest to the pharmaceutical industry (S. 515/H.R. 1260)
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369; H.R. 3962, H.R. 3590, H.R. 4899)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry with respect to possible changes in, or implementation of, the health care reform legislation - the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (H.R. 4313, P.L. 111-142), Tax Extenders Legislation (H.R. 4853, P.L. 111-312)
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Oct. 19, 2010.
Original Filing: 300326315.xml
Lobbying Issues
Patent Reform - Issues of interest to the pharmaceutical industry (S. 515/H.R. 1260)
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369; H.R. 3962, H.R. 3590, H.R. 4899)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry with respect to possible changes in, or implementation of, the health care reform legislation - the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (H.R. 4313, P.L. 111-142)
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2010
In Q2, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on July 20, 2010.
Original Filing: 300297252.xml
Lobbying Issues
Patent Reform - Issues of interest to the pharmaceutical industry (S. 515/H.R. 1260)
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369; H.R. 3962, H.R. 3590, H.R. 4899)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry with respect to possible changes in, or implementation of, the health care reform legislation - the Patient Protection and Affordable Care Act (H.R. 3590) and the Health Care and Education Reconciliation Act of 2010 (H.R. 4872)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Extension of Research and Development Tax Credit (H.R. 4313)
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2010
In Q1, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on April 20, 2010.
Original Filing: 300274528.xml
Lobbying Issues
Patent Reform - Issues of interest to the pharmaceutical industry (S. 515/H.R. 1260)
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369; H.R. 3962, H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry in the health care reform legislation - the Patient Protection and Affordable Care Act (H.R. 3590) and the Health Care and Education Reconciliation Act of 2010 (H.R. 4872)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Jan. 19, 2010.
Original Filing: 300238729.xml
Lobbying Issues
Patent Reform - Issues of interest to the pharmaceutical industry (S. 515/H.R. 1260)
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369; H.R. 3962)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry in the health care reform legislation, Affordable Health Choices Act (S. 1679, H.R. 3590; America's Affordable Health Choices Act (H.R. 3200, H.R. 3962)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on Oct. 19, 2009.
Original Filing: 300211726.xml
Lobbying Issues
Patent Reform-Issues of interest to the pharmaceutical industry (S. 515/HR 1260)
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369;
HR 3200)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues of interest to the pharmaceutical industry in the health care reform legislation, Affordable Health Choices Act
(S. 1679); America's Healthy Future Act (S. ____) and America's Affordable Health Choices Act (H.R. 3200)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on July 17, 2009.
Original Filing: 300182406.xml
Lobbying Issues
Development of health care reform legislation (no bill numbers yet)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Adequacy of Appropriations for the Food and Drug Administration (S. 1406)
1st Quarter, 2009
In Q1, Knight Capitol Consultants lobbied for sanofi-aventis, U.S., Inc. , earning $30,000. The report was filed on April 17, 2009.
Original Filing: 300154624.xml
Lobbying Issues
Development of health care reform legislation (no specific bills yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor general issues of interest to pharmaceutical industry (no specific bills)
Agencies Lobbied
U.S. Senate
4th Quarter, 2008
In Q4, Knight Capitol Consultants lobbied for Sanofi-Aventis , earning $20,000. The report was filed on Jan. 16, 2009.
Original Filing: 300124032.xml
Lobbying Issues
Development of health care reform legislation
3rd Quarter, 2008
In Q3, Knight Capitol Consultants lobbied for Sanofi-Aventis , earning $20,000. The report was filed on Oct. 17, 2008.
Original Filing: 300099754.xml
Lobbying Issues
Medicare Improvements for Patients and Providers Act of 2008 (H.R. 6331, S. 3101) - development of compendia for reimbursement of off-label drug use.
Lobbying Issues
Health care reform and development of legislation to assess the comparative effectiveness of medical therapies.
2nd Quarter, 2008
In Q2, Knight Capitol Consultants lobbied for Sanofi-Aventis , earning $20,000. The report was filed on July 16, 2008.
Original Filing: 300067800.xml
Lobbying Issues
Centers for Medicare & Medicaid Services development of compendia for reimbursement of off-label drug use (S.3101, H.R. 6331)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Development of legislation to assess the comparative effectiveness of medical therapies
1st Quarter, 2008
In Q1, Knight Capitol Consultants lobbied for Sanofi-Aventis , earning $20,000. The report was filed on April 18, 2008.
Original Filing: 300042928.xml
Lobbying Issues
Development of compendia for certain pharmaceutical reimbursement
1st Quarter, 2008
Ms. Patricia Knight filed a lobbying registration on March 13, 2008 to represent Sanofi-Aventis, effective Feb. 1, 2008.
Original Filing: 300030430.xml
Issue(s) they said they’d lobby about: Centers for Medicare&Medicaid Services development of compendia for reimbursement of off-label drug use. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...